Sign in
Not yet taking people in South KoreaNo phase

Tests a single-lead ECG patch for heart rhythm monitoring in hospitalized adults

Tests a heart rhythm patch in adults needing hospital heart monitoring.

Key facts

Who runs it
Yonsei University
Where
Seoul, South KoreaSee the site
Trial code
Registry title
Evaluation of a Single-lead ECG Patch-based Telemetry System for In-hospital Monitoring
Status
Not yet recruiting
People taking part
100 people, planned
Started
Dec 2025
Planned end
Sept 2026
Type of study
Interventional
Treatments tested
  • MEMO-Cue-based telemetry monitoring
Record updated
3 December 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults in hospital who need continuous heart rhythm (ECG) monitoring. They wear a small ECG patch while in hospital.

Age
19 years or older
Sex
All
Disease stage
Patients who need heart rhythm (telemetry ECG) monitoring during a hospital stay.

Main reasons for not taking part

  • Known allergy to adhesives or hydrogel
  • Skin wounds where the patch would be placed
  • Implanted heart devices such as a pacemaker or ICD
  • Skin cancer, rash, skin disorders, keloid or skin injury, now or in the past
  • Cognitive impairment that prevents understanding the study and giving consent

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Adults aged 19 years or older who provide written informed consent for participation
  • Patients requiring in-hospital telemetry electrocardiogram monitoring during hospitalization

Who cannot take part

  • Presence of skin wounds at the intended application site of the investigational device
  • Known hypersensitivity or allergic reaction to adhesives or hydrogel
  • Implanted cardiac electronic devices such as pacemakers, ICDs, or other CIEDs
  • Current or past history of skin cancer, rash, dermatologic disorders, keloid formation, or skin injury
  • Any condition judged by the investigator to increase risk or make participation inappropriate
  • Cognitive impairment that precludes understanding of study information or voluntary consent

Where in South Korea

  • Yonsei University College of MedicineSeoul, South KoreaNot yet recruiting

About the trial

What the trial wants to find out

"This investigator-initiated, prospective, single-center clinical study evaluates the performance and clinical utility of a single-lead electrocardiogram (ECG) patch-based telemetry system for hospitalized patients who require in-hospital telemetry ECG monitoring. The system integrates real-time centralized surveillance (MEMO-Cue) with post-hoc analytic review (MEMO-Care) using ECG signals recorded by the MEMO Patch M, aiming to enable timely recognition of clinically important arrhythmias and to inform treatment decisions under routine inpatient conditions.

Read full original descriptionShow less

Adults (≥19 years) indicated for continuous ECG monitoring during admission are enrolled after written informed consent, with a planned sample size of 100 to yield approximately 90 evaluable participants (10% anticipated dropout). The design does not include randomization or blinding. Study procedures include a screening visit (eligibility and baseline data), an inpatient monitoring period of at least 12 hours and up to 8 days with simultaneous MEMO-Cue monitoring and MEMO Patch M recording, and an end-of-visit assessment when MEMO-Care analytic results become available. Concomitant therapies deemed clinically necessary are permitted and documented, and adverse events are prospectively assessed.

Clinical utility endpoints quantify care impact and timeliness: (1) rate of treatment plan changes (e.g., initiation or modification of anticoagulants or antiarrhythmic drugs, cardioversion scheduling, device implantation, or other actions); (2) time to recognition (days) of major arrhythmias-atrial fibrillation (AF), ventricular tachycardia (VT), pause, ventricular premature complex (VPC), and supraventricular tachycardia (SVT)-based on MEMO-Cue alarms or MEMO-Care results with objective confirmation; (3) reduction ratio in recognition time when identified earlier by MEMO-Cue versus MEMO-Care; and (4) proportion of participants with shortened recognition time by MEMO-Cue.

Clinical performance endpoints assess detection characteristics and agreement between MEMO-Cue alarms and MEMO-Care findings: (1) clinical sensitivity (true positive / [true positive + false negative]); (2) precision, i.e., positive predictive value (true positive / [true positive + false positive]); and (3) positive concordance rate (proportion of MEMO-Care-detected arrhythmias alerted by MEMO-Cue). Safety is captured as treatment-emergent adverse events after device application, including device-related skin reactions, detachment, or signal dropouts, with severity graded per NCI-CTCAE v5.0 and relationship to device recorded.

By characterizing real-time patch-based telemetry alongside analytic review and its influence on diagnostic timing and management, the study aims to generate practical evidence supporting feasibility, reliability, and workflow compatibility of single-lead patch telemetry for in-hospital ECG monitoring.

The group in the trial

  • MEMO-CueTreatment being tested

    Participants receive continuous in-hospital ECG monitoring using the MEMO-Cue system, which combines a single-lead patch device with real-time telemetry software. Monitoring lasts 12 hours to 8 days, and arrhythmia detection performance is compared with retrospective analysis using MEMO Care.

    Treatment: MEMO-Cue-based telemetry monitoring

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Investigator-initiated Trial to Evaluate the Performance and Utility of a Single-lead Electrocardiogram Patch-based Telemetry System in Patients Requiring In-hospital Telemetry Electrocardiogram Monitoring During Hospitalization
Plain-language title
Tests a single-lead ECG patch for heart rhythm monitoring in hospitalized adultsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
3 December 2025